Matthew McKee, DO
Sleep Medicine · Roosevelt, UTNPI 1891149621
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,766 of the $2,026 with a category attached, or 87.2%. It is spread thinly across 23 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $911, more than ten times the $60 reported in 2022. That places this record below the midpoint for sleep medicine clinicians in UT, where the typical reported total is $2,026.
Across 92 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$312
- AbbVie$270
- AstraZeneca$254
- Harmony Biosciences LLC$252
- Jazz Pharmaceuticals Inc.$200
- Lilly USA, LLC$114
- plus $623 from 17 others
What the payments were for
- Food & beverage$1,76687%
- Education$26013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 8 | $312 |
| AbbVie | 17 | $270 |
| AstraZeneca | 14 | $254 |
| Harmony Biosciences LLC | 8 | $252 |
| Jazz Pharmaceuticals Inc. | 2 | $200 |
| Lilly USA, LLC | 7 | $114 |
| Corcept Therapeutics | 5 | $89 |
| Xeris Pharmaceuticals, Inc. | 4 | $81 |
| Boehringer Ingelheim | 3 | $60 |
| Idorsia Pharmaceuticals US Inc | 4 | $54 |
| Johnson & Johnson | 3 | $49 |
| Axsome Therapeutics, Inc. | 3 | $44 |
| Dexcom, Inc. | 2 | $37 |
| Verona Pharma, Inc. | 1 | $35 |
| Novo Nordisk | 2 | $31 |
| Pfizer | 2 | $29 |
| Lundbeck LLC | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Itamar Medical Inc | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| Organon | 1 | $14 |
| BETA Bionics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wakix$120
How this compares
$2,026 in reported general payments places this provider in the 50th percentile of 20 sleep medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 147 | $151,230 |
| EliquisApixaban | 90 | $78,622 |
| XareltoRivaroxaban | 65 | $68,281 |
| FarxigaDapagliflozin Propanediol | 77 | $59,766 |
| JardianceEmpagliflozin | 66 | $53,867 |
| TrulicityDulaglutide | 40 | $39,524 |
| RybelsusSemaglutide | 26 | $31,741 |
| MounjaroTirzepatide | 20 | $21,481 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $21,051 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $17,215 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $17,185 |
| LinzessLinaclotide | 13 | $12,824 |
| MyrbetriqMirabegron | 12 | $11,626 |
| ButransBuprenorphine | 16 | $10,812 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 52 | $6,926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $31 | $182,971173 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $254 | $82,915131 claims |
| PfizerEliquis | $29 | $78,62290 claims |
| Johnson & JohnsonXarelto | $49 | $68,28165 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $114 | $61,00560 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $60 | $60,76380 claims |
| AbbVieLinzess | $270 | $12,82413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 20 sleep medicine providers in Utah.
Other sleep medicine in Roosevelt
- Kirk WatkinsSt George$248K
- Seth WallaceLogan$118K
- Chitra LalSalt Lake City$94K
- Krishna SundarProvo$17K
- Robert MazzolaSalt Lake City$12K
- John StaheliProvo$9K
- Nicholas AndersonSalt Lake City$7K
- Sanjay KajiSalt Lake City$5K
- Garrett BirdRiverton$4K
- Shannon JenkinsSalt Lake City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.